Supporting Dewpoint’s novel condensate modulating approach to drug previously ‘undruggable’ therapeutic targets, guided by ...
The collaboration is another vote of confidence in Dewpoint’s biomolecular condensates research, which had already attracted ...
As part of the deal, Dewpoint can expect an undisclosed upfront payment from Mitsubishi Tanabe Pharma Corporation (MTPC) in ...
Mitsubishi Tanabe Pharma is offering Dewpoint Therapeutics up to $480 million biobucks in a new research pact centering ...
Dewpoint Therapeutics CEO Ameet Nathwani stated: “This partnership underscores the transformative potential of our small ...
Mitsubishi Tanabe Pharma Corporation obtains an option for a global license to develop and commercialize the novel TDP-43 ...
Privately-held Dewpoint Therapeutics, a Boston, USA, biotech developing therapeutics by targeting biomolecular condensates, ...
Dewpoint Therapeutics Inc. and Mitsubishi Tanabe Pharma Corp. have entered a research collaboration worth up to $480 million ...
Biotechnology company Dewpoint Therapeutics is translating condensate science into breakthrough medicine for diseases with high unmet need. Dewpoint has built an artificial intelligence (AI ...
BEHIND THE FRONT Behind yesterday’s cold front, high pressure is building into the area, yielding drier air. UP AND DOWN ...